share_log

信达生物(01801.HK)：一季度取得总产品收入超过17亿元 同比强劲增长超60%

Cinda Biotech (01801.HK): Total product revenue in the first quarter exceeded 1.7 billion yuan, a strong year-on-year increase of more than 60%

Gelonghui Finance ·  Apr 30 05:03

On April 30, Gelonghui | Cinda Biotech (01801.HK) announced that in the first quarter of 2024, the company achieved total product revenue exceeding RMB 1.7 billion, a strong increase of over 60% over the previous year. The overall product portfolio continued to grow rapidly during the quarter, thanks to advantages such as broad indication potential, health insurance coverage and complete access channels. Daboshu(Cindilizumab Injection) continues to achieve strong sales performance and a stable market leading position. Other products have also grown significantly. In particular, new products have accelerated growth and continued to increase their contribution.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment